Short-read Sequencing Market Size & Share, By Product (Instruments, Consumables), Workflow, Application, End-Use - Growth Trends, Regional Insights (U.S., Japan, South Korea, UK, Germany), Competitive Positioning, Global Forecast Report 2025-2034

Perspectiva del mercado:

Short-read Sequencing Market size is predicted to reach USD 38.32 billion by 2034, up from USD 7.26 billion in 2024, reflecting a CAGR of over 18.1% during the forecast period from 2025 to 2034. The industry revenue for 2025 is projected to be USD 8.47 billion.

• Base Year Value (2024): USD 7.26 billion
• CAGR (2025-2034): 18.1%
• Forecast Year Value (2034): USD 38.32 billion
• Historical Data Period: 2021-2034
• Largest Region: North America
• Forecast Period: 2025-2034

Dinámica del mercado:

Growth Drivers & Opportunities:

The short-read sequencing market is poised for significant expansion, driven by several key factors. One of the primary growth drivers is the increasing demand for personalized medicine. As the healthcare landscape shifts towards targeted therapies, the ability to sequence genomes rapidly and accurately becomes essential. This has led to an uptick in investments in genomic research and technologies, creating a fertile environment for short-read sequencing solutions. Additionally, advancements in sequencing technologies, such as the development of faster and more cost-effective platforms, are drawing attention from research institutions and clinical laboratories alike. These innovations not only facilitate large-scale studies but also make genetic testing more accessible to a broader audience.

Moreover, the rise of biobanks and genomic databases is fostering collaborations and encouraging more comprehensive genetic analyses. Researchers are eager to explore the nuances of genetic variations, which further fuels interest in short-read sequencing. Another significant opportunity lies in the expanding applications of sequencing technologies in various fields, including oncology, rare disease research, and infectious disease surveillance. As industries recognize the value of integrating genomics into their workflows, the market for short-read sequencing will continue to grow.

Report Scope

Report Coverage	Details
Segments Covered	Product, Workflow, Application, End-Use
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	Illumina,, Thermo Fisher Scientific,, Pacific Biosciences of California,, BGI, QIAGEN, Agilent Technologies, PerkinElmer,, ProPhase Labs, (Nebula Genomics), Psomagen, Azenta US, (GENEWIZ)

Industry Restraints:

Despite its promising outlook, the short-read sequencing market faces several challenges that may hinder its growth. One major restraint is the technical limitations associated with short-read sequencing, particularly in accurately capturing complex genomic regions such as repetitive areas and structural variants. These limitations can lead to incomplete or misleading results, ultimately affecting clinical decisions and research outcomes. Additionally, the data generated from sequencing efforts can be overwhelmingly vast, leading to challenges in data management, analysis, and interpretation. Many organizations lack the necessary bioinformatics capabilities to fully leverage this data, which can slow down the progress of genomic research.

Furthermore, regulatory hurdles and ethical concerns related to genetic data usage present persistent challenges. The management of sensitive genetic information requires stringent compliance with privacy regulations, which can complicate the development and deployment of short-read sequencing technologies. Cost considerations also play a crucial role; while the technology is becoming more affordable, high initial capital expenditure and ongoing operational costs can deter potential adopters. Collectively, these restraints create a complex operating environment for stakeholders in the short-read sequencing market.

Pronóstico Regional:

North America

The North American short-read sequencing market is primarily driven by the advanced healthcare infrastructure, high R&D investments, and a significant presence of prominent sequencing technology companies. The United States is the largest contributor in this region, largely due to extensive funding in genomics research and the adoption of personalized medicine initiatives. Canada is also witnessing a steady progression in the integration of genomic technologies within clinical practices, bolstered by government support and increasing public awareness about the benefits of genomic medicine. The focus on precision health and the growing need for innovative diagnostic solutions are anticipated to position North America as a key market player.

Asia Pacific

In the Asia Pacific region, the short-read sequencing market is experiencing rapid growth, with countries like China and Japan leading the way. China's aggressive investment in biotechnology and genomics, combined with its focus on expanding healthcare capabilities, is expected to result in significant market expansion. Japan, known for its technological advancements, is also enhancing its genomics research capabilities, positioning itself as a critical player. South Korea is emerging as a notable competitor in the sequencing landscape, driven by its robust bioinformatics sector and healthcare advancements. Overall, the region's growing biotechnology sector and rising healthcare expenditures are expected to further accelerate market growth.

Europe

The European short-read sequencing market is characterized by a diverse landscape with key players in the UK, Germany, and France. The UK stands out due to its strong emphasis on public health genomics and the integration of genomic data in clinical settings, bolstered by initiatives like the 100,000 Genomes Project. Germany is another significant player, renowned for its cutting-edge technology and strong focus on life sciences research, enabling substantial investments in genomic studies. Meanwhile, France is also increasing its presence in the market by promoting genomic research and incorporating sequencing technologies in various healthcare applications. The European market is projected to grow steadily, supported by collaborations between academic institutions and the biotechnology industry.

Análisis de segmentación:

In terms of segmentation, the global Short-read Sequencing market is analyzed on the basis of Product, Workflow, Application, End-Use.

Product Segment

The short-read sequencing market is primarily divided into instruments, reagents, and services. Among these, instruments are projected to hold the largest market share due to their crucial role in the sequencing process. Advancements in sequencing technologies are driving the demand for high-throughput and cost-effective sequencers. On the other hand, reagents, including DNA polymerases and library preparation kits, are anticipated to experience robust growth as they are essential for enhancing sequencing accuracy and efficiency. Services, especially sequencing services offered by specialized laboratories, are also growing rapidly, driven by the increasing number of research projects and clinical applications requiring sequencing expertise.

Workflow Segment

In terms of workflow, the market is categorized into pre-sequencing, sequencing, and post-sequencing processes. The sequencing component is expected to dominate the market size, as it represents the core function of short-read sequencing technologies. Pre-sequencing workflows, which include sample preparation and library construction, are projected to witness significant growth due to ongoing improvements in protocols that streamline these processes. Additionally, post-sequencing analysis and data interpretation are becoming increasingly important as the volume of sequenced data rises; therefore, this segment is also positioned for noteworthy growth as bioinformatics capabilities evolve to manage complex datasets.

Application Segment

The applications of short-read sequencing include genomics, transcriptomics, epigenomics, and others, such as metagenomics. The genomics segment holds the largest market size, primarily due to its widespread use in various sectors like personalized medicine and genetic research. Transcriptomics is also gaining traction as RNA sequencing becomes essential for understanding gene expression, indicating rapid growth potential in this area. Epigenomics is emerging as a significant player as researchers delve into the regulatory mechanisms affecting gene expression, further driving demand in the market.

End-Use Segment

In the end-use category, the market is segmented into academic & research institutes, hospitals & clinics, pharmaceutical & biotechnology companies, and others. Academic and research institutes are likely to occupy the largest market share, benefiting from increased funding for genomics research and collaborations. Pharmaceutical and biotechnology companies are projected to experience the fastest growth rate as they harness short-read sequencing for drug development and biomarker discovery, propelled by the increasing focus on precision medicine. Hospitals and clinical labs are also evolving, with growing demand for advanced sequencing technologies for diagnostics and personalized healthcare solutions.

Panorama competitivo:

The competitive landscape in the Short-read Sequencing Market is characterized by a diverse range of companies that are constantly innovating to enhance their sequencing technologies and expanding their product offerings. Key players are investing heavily in research and development to improve the accuracy, speed, and cost-effectiveness of their sequencing platforms. Collaborations, mergers, and acquisitions are prevalent as companies seek to strengthen their market position and broaden their technological capabilities. Additionally, the demand for personalized medicine and genomic research is driving competition, as firms aim to capture a larger share of the growing market by providing sophisticated solutions for a variety of applications, including oncology, microbiomics, and agricultural genomics.

Top Market Players

1. Illumina Inc.

2. Thermo Fisher Scientific Inc.

3. PacBio

4. Roche Holding AG

5. BGI Group

6. Qiagen N.V.

7. Oxford Nanopore Technologies

8. SeqLL Inc.

9. Genomatix Software GmbH

10. 10x Genomics Inc.